Immunomic Therapeutics Doses First Participant in Phase 1 Trial of ITI-9001 Therapeutic Vaccine for Japanese Cedar Pollen Allergy
Immunomic Therapeutics Inc. (ITI), a clinical-stage biotechnology company and subsidiary of HLB, has announced the dosing of the first participant in its Phase 1 clinical trial evaluating ITI-9001, an investigational therapeutic vaccine being developed for the treatment of Japanese cedar pollen allergy. The milestone marks the official initiation of clinical testing for the company’s next-generation immunotherapy and represents an important step toward developing a disease-modifying treatment for one of Japan’s most widespread allergic conditions.
The first participant received the investigational therapy less than one month after the clinical trial application received clearance from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), highlighting the company’s ability to rapidly transition from regulatory approval to active clinical development.
According to Immunomic Therapeutics, the participant has successfully completed the initial post-dose monitoring period, and no significant adverse events or major safety concerns have been reported following administration of the vaccine. While the study remains in its earliest stages, the successful dosing of the first participant establishes the foundation for evaluating the safety, tolerability, and immune response generated by the novel therapeutic candidate.
The Phase 1 study represents the first clinical evaluation of ITI-9001 in patients with Japanese cedar pollen allergy and is expected to generate important data that will guide future clinical development as the company seeks to introduce a new class of immunotherapy capable of addressing the underlying immune mechanisms responsible for allergic disease.
Addressing a Major Public Health Challenge in Japan
Japanese cedar pollen allergy, commonly known as cedar pollinosis, is one of the most prevalent allergic diseases in Japan and has become an increasingly significant public health concern over the past several decades.
Each spring, enormous quantities of pollen released by Japanese cedar trees trigger allergic reactions in millions of individuals throughout the country. Symptoms frequently include sneezing, nasal congestion, runny nose, itchy eyes, watery eyes, coughing, and throat irritation. In many cases, symptoms can persist for weeks or even months during the pollen season, significantly affecting quality of life, workplace productivity, school performance, and overall daily functioning.
According to Immunomic Therapeutics, approximately 48 million people in Japan are affected by Japanese cedar pollen allergy, making it one of the country’s most common chronic allergic disorders.
The large number of affected individuals creates substantial healthcare and economic burdens, increasing demand for more effective long-term treatment options capable of providing lasting symptom control.
Although several therapeutic approaches are currently available, many patients continue to experience persistent symptoms despite treatment, underscoring the need for innovative therapies that address the underlying cause of the disease rather than simply managing seasonal symptoms.
Rapid Progress Following PMDA Clearance
The initiation of patient dosing occurred less than one month after Japan’s Pharmaceuticals and Medical Devices Agency cleared the clinical trial application for ITI-9001.
Moving from regulatory authorization to first-patient dosing within such a short timeframe demonstrates efficient clinical trial preparation, including site activation, patient recruitment, protocol implementation, and operational readiness.
Rapid trial initiation can be particularly important in allergy research, where seasonal patterns often influence study timelines and participant availability.
By successfully launching the Phase 1 study shortly after regulatory clearance, Immunomic Therapeutics has positioned itself to begin collecting valuable clinical data while maintaining momentum in the development of its investigational therapy.
The absence of significant safety concerns following the first administration also provides an encouraging initial step as enrollment continues.
Phase 1 Trial Designed to Evaluate Safety and Immune Response
The Phase 1 clinical trial has been designed as a randomized, placebo-controlled, single-center study involving adults between 18 and 65 years of age who have been diagnosed with Japanese cedar pollen allergy.
Early-stage clinical studies primarily focus on establishing the safety profile of investigational therapies while also generating preliminary information regarding biological activity and appropriate dosing.
The study will evaluate multiple dose levels of ITI-9001, beginning with low-dose and high-dose treatment cohorts.
Researchers will carefully monitor participants for adverse events, tolerability, and other safety parameters in order to determine the most appropriate dose for continued clinical development.
Following dose selection, investigators will compare the selected treatment dose with placebo while evaluating both safety and immunogenicity.
Immunogenicity assessments will examine how the immune system responds to the vaccine, providing early indications regarding whether ITI-9001 successfully stimulates the desired immune mechanisms believed to contribute to long-term therapeutic benefit.
The data generated during Phase 1 will provide the scientific foundation for designing future studies evaluating the vaccine’s clinical effectiveness.
A Therapeutic Vaccine Rather Than a Preventive Vaccine
Unlike traditional preventive vaccines designed to protect healthy individuals from infectious diseases, ITI-9001 is being developed as a therapeutic vaccine intended to treat individuals who already suffer from Japanese cedar pollen allergy.
The goal of therapeutic vaccination is not to prevent exposure to pollen but rather to retrain or modulate the immune system so that it responds differently when exposed to allergenic proteins.
Current allergy treatments generally focus on symptom management through medications such as antihistamines, nasal corticosteroids, decongestants, or other therapies that temporarily reduce allergic inflammation.
Although these medications often provide symptom relief, they do not fundamentally change the immune processes responsible for allergic disease.
ITI-9001 seeks to offer a different therapeutic approach by modifying immune responses directed against cedar pollen allergens, potentially providing longer-lasting clinical benefits.
If successful, this strategy could reduce dependence on continuous seasonal medication while addressing the underlying immune dysfunction driving allergic reactions.
Combining the UNITE® Platform with Self-Amplifying RNA Technology
ITI-9001 incorporates two advanced biotechnology platforms that distinguish it from conventional allergy treatments.
The vaccine combines Immunomic Therapeutics’ proprietary UNITE® platform with self-amplifying RNA (saRNA) technology.
The UNITE platform utilizes lysosome-associated membrane protein (LAMP) technology to improve antigen presentation within immune cells.
By fusing target antigens with LAMP, the vaccine is designed to direct antigens toward intracellular pathways that enhance presentation to immune cells responsible for generating T-cell responses.
Efficient antigen presentation represents an essential component of effective immune modulation because it influences how the immune system recognizes and responds to disease-associated proteins.
The second component of the technology involves self-amplifying RNA.
Unlike conventional messenger RNA, self-amplifying RNA contains genetic elements that allow intracellular replication of the encoded RNA after administration, potentially increasing antigen production while requiring lower administered doses.
This approach may improve immune activation while enhancing manufacturing efficiency and reducing the amount of RNA needed per vaccination.
The combination of these technologies is intended to produce stronger, more durable cellular immune responses capable of altering the abnormal immune activity associated with allergic disease.
Targeting the CryJ2 Allergen
ITI-9001 specifically targets CryJ2, one of the principal allergenic proteins found in Japanese cedar pollen.
CryJ2 is recognized by the immune systems of many individuals suffering from cedar pollinosis and plays an important role in triggering allergic reactions during pollen exposure.
By directing immune responses toward this major allergen, the vaccine aims to modify the body’s reaction when naturally exposed to cedar pollen.
Rather than producing exaggerated allergic responses characterized by inflammation and symptom development, the therapeutic objective is to promote a more balanced immune response capable of reducing disease severity.
Targeting a well-characterized allergen also provides researchers with measurable biological markers that can be evaluated during clinical development.
Potential to Address Limitations of Current Therapies
Existing treatments for Japanese cedar pollen allergy include antihistamines, nasal corticosteroids, leukotriene inhibitors, and allergen immunotherapy.
While these approaches benefit many patients, each has important limitations.
Symptom-relieving medications typically require repeated administration throughout the allergy season and may not provide adequate control for all patients.
Traditional allergen immunotherapy can modify disease progression but often requires prolonged treatment schedules extending over several years, involving numerous injections or daily sublingual therapy.
Many patients discontinue treatment before completing the recommended course due to inconvenience or limited adherence.
ITI-9001 has been designed with the objective of overcoming some of these limitations by inducing robust immune modulation through advanced vaccine technology.
Although its clinical effectiveness remains to be established, the investigational therapy seeks to provide durable disease-modifying benefits that extend beyond temporary symptom relief.
If future clinical studies confirm these objectives, ITI-9001 could represent an important advancement in allergy treatment.
Company Leadership Highlights Development Goals
Dong Gun Kim, Chief Executive Officer of Immunomic Therapeutics, emphasized that the company’s scientific strategy extends beyond symptom management.
According to Kim, ITI-9001 has been specifically designed to modulate the immune system and address the biological mechanisms responsible for Japanese cedar pollen allergy rather than merely suppressing allergic symptoms after they occur.
He explained that the Phase 1 clinical trial represents an important opportunity to establish both the safety profile and initial immunogenicity of the investigational vaccine.
The information generated during the study will guide subsequent development as Immunomic Therapeutics continues advancing the program toward later-stage clinical evaluation.
Kim also expressed optimism that ITI-9001 could ultimately emerge as a next-generation immunotherapy capable of offering meaningful benefits to millions of individuals affected by Japanese cedar pollen allergy.
The dosing of the first participant marks the beginning of clinical evaluation for one of the most innovative investigational therapies currently being developed for Japanese cedar pollen allergy. By combining Immunomic Therapeutics’ proprietary UNITE® platform with self-amplifying RNA technology, ITI-9001 seeks to fundamentally change how allergic disease is treated through targeted immune modulation rather than temporary symptom suppression.
As enrollment continues in the Phase 1 study, researchers will closely monitor safety, tolerability, and immune responses while gathering the first clinical evidence regarding the vaccine’s therapeutic potential. Given the enormous number of individuals affected by Japanese cedar pollen allergy throughout Japan, successful development of a disease-modifying immunotherapy could address a substantial unmet medical need.
Although additional clinical studies will be required to establish long-term efficacy and safety, the initiation of this first-in-human trial represents an important milestone in Immunomic Therapeutics’ efforts to develop innovative immunotherapies that leverage advanced RNA and antigen-presentation technologies to improve outcomes for patients living with chronic allergic diseases.